Millennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA)

Millennium Management LLC lifted its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 71.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 482,263 shares of the company's stock after buying an additional 201,599 shares during the period. Millennium Management LLC owned approximately 0.28% of Savara worth $1,481,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Farallon Capital Management LLC boosted its holdings in shares of Savara by 49.9% in the 4th quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company's stock worth $20,983,000 after buying an additional 2,275,000 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in Savara by 314.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company's stock worth $217,000 after acquiring an additional 53,547 shares during the period. Deutsche Bank AG raised its position in Savara by 6.1% in the fourth quarter. Deutsche Bank AG now owns 927,595 shares of the company's stock worth $2,848,000 after acquiring an additional 53,054 shares during the period. Deerfield Management Company L.P. Series C grew its position in shares of Savara by 23.2% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock valued at $24,449,000 after acquiring an additional 1,498,223 shares during the period. Finally, Cubist Systematic Strategies LLC grew its position in shares of Savara by 91.3% during the 4th quarter. Cubist Systematic Strategies LLC now owns 103,099 shares of the company's stock valued at $317,000 after acquiring an additional 49,204 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on SVRA. Evercore ISI lowered their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. Wells Fargo & Company reduced their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 28th. HC Wainwright lowered Savara from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $6.00 to $2.00 in a report on Thursday, May 29th. Finally, Guggenheim reissued a "buy" rating and set a $8.00 price objective (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Savara has a consensus rating of "Moderate Buy" and a consensus price target of $7.17.

Savara Stock Performance

Savara stock traded up $0.06 during mid-day trading on Friday, reaching $2.44. The company's stock had a trading volume of 791,318 shares, compared to its average volume of 1,427,524. Savara Inc has a 12-month low of $1.89 and a 12-month high of $5.11. The company has a market capitalization of $421.72 million, a P/E ratio of -5.67 and a beta of 0.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The firm's fifty day moving average price is $2.88 and its two-hundred day moving average price is $2.92.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.12). Sell-side analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.